Peter H. Ros, RA serves as Vice President of Finance at Lava Therapeutics, a biotechnology company focused on developing bispecific gamma-delta T cell engagers to transform cancer therapy, since January 2020. Prior to joining Lava Therapeutics, he served in various roles at Genmab, including as Senior Director of Accounting and Finance from October 2018 to December 2019, Senior Director of Finance and Accounting, R&D Operations from July 2015 to September 2018 and (Senior) Director of Finance from November 2001 to June 2015. Mr. Ros also served as an Accountant at PricewaterhouseCoopers from September 1993 to April 1999.
He received a RA title in accountancy from VU Amsterdam (1998) and his HEAO RA degree in accountancy from Windesheim University (1993).
